PD8-07 A PROSPECTIVE RANDOMIZED DOUBLE-BLINDED PLACEBO CONTROL TRIAL ON THE EFFECTS OF CRANBERRY SUPPLEMENTATION ON BACTERIAL COLONIZATION AND SYMPTOMATIC URINARY TRACT INFECTIONS IN FEMALES WITH NEUROGENIC BLADDER DYSFUNCTION DEPENDENT ON SELF CATHETERIZATION

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Jason Scovell ◽  
Sophie Fletcher ◽  
Julie Stewart ◽  
Rose Khavari
Keyword(s):  
Urinary Tract ◽  
Neurogenic Bladder ◽  
Urinary Tract Infections ◽  
Bladder Dysfunction ◽  
Bacterial Colonization ◽  
Placebo Control Trial ◽  
Placebo Control ◽  
Neurogenic Bladder Dysfunction ◽  
Tract Infections ◽  
Double Blinded

scholarly journals Neurogenic Bladder

2012 ◽  
Vol 2012 ◽  
pp. 1-16 ◽  
Author(s):  
Peter T. Dorsher ◽  
Peter M. McIntosh
Keyword(s):  
Urinary Incontinence ◽  
Urinary Tract ◽  
Neurogenic Bladder ◽  
Urinary Tract Infections ◽  
Bladder Dysfunction ◽  
Upper Urinary Tract ◽  
Neurogenic Bladder Dysfunction ◽  
Surgical Interventions ◽  
Bladder Retraining ◽  
Tract Infections

Congenital anomalies such as meningomyelocele and diseases/damage of the central, peripheral, or autonomic nervous systems may produce neurogenic bladder dysfunction, which untreated can result in progressive renal damage, adverse physical effects including decubiti and urinary tract infections, and psychological and social sequelae related to urinary incontinence. A comprehensive bladder-retraining program that incorporates appropriate education, training, medication, and surgical interventions can mitigate the adverse consequences of neurogenic bladder dysfunction and improve both quantity and quality of life. The goals of bladder retraining for neurogenic bladder dysfunction are prevention of urinary incontinence, urinary tract infections, detrusor overdistension, and progressive upper urinary tract damage due to chronic, excessive detrusor pressures. Understanding the physiology and pathophysiology of micturition is essential to select appropriate pharmacologic and surgical interventions to achieve these goals. Future perspectives on potential pharmacological, surgical, and regenerative medicine options for treating neurogenic bladder dysfunction are also presented.

scholarly journals Immunotherapy to reduce frequency of urinary tract infections in people with neurogenic bladder dysfunction; a pilot randomised, placebo-controlled trial

2020 ◽  
Vol 34 (12) ◽  
pp. 1458-1464
Author(s):  
Derick T Wade ◽  
James Cooper ◽  
Nicholas Peckham ◽  
Maurizio Belci
Keyword(s):  
Urinary Tract ◽  
Neurogenic Bladder ◽  
Urinary Tract Infections ◽  
Bladder Dysfunction ◽  
Controlled Trial ◽  
Control Group ◽  
Neurogenic Bladder Dysfunction ◽  
Matching Placebo ◽  
Cord Injury ◽  
Tract Infections

Objective: To establish the feasibility of a randomized, placebo-controlled trial to investigate the effect of a specific immunotherapy bacterial lysate OM-89 (Uro-Vaxom®) in reducing the frequency of urinary tract infections in people with neurogenic bladder dysfunction. Design: A parallel-group, double-blind, randomized, placebo-controlled trial. Setting: Patients at home, recruited through out-patient contact, social media and patient support groups. Subjects: People with a spinal cord injury, multiple sclerosis, transverse myelitis or cauda equina syndrome who had suffered three or more clinically diagnosed urinary tract infections treated with antibiotics over the preceding 12 months. Interventions: All participants took one capsule of oral OM-89 immunotherapy (6 mg) or matching Placebo (randomisation ratio 1:1), once daily in the morning for 3 months. Main measures: The primary outcome was occurrence of a symptomatic urinary tract infection treated with an antibiotic, assessed at 3 and 6 months. Feasibility measures included recruitment, retention and practical difficulties. Results: Of 115 patients screened, 49 were recruited, one withdrew before randomization, and 23 were allocated to the control group receiving matching placebo. Six participants, all in the control group, discontinued the intervention; all participants provided full data at both follow-up times. Over 6 months, 18/25 active group patients had 55 infections, and 18/23 control group patients had 47 infections. Most research and clinical procedures were practical, and acceptable to participants. Conclusion: It is feasible to undertake a larger trial. We recommend broader inclusion criteria to increase eligibility and generalizability.

scholarly journals Urinary Tract Infections with Non-Escherichia coli Pathogens in Children: An Observational Study

2020 ◽  
Vol 12 (4) ◽  
Author(s):  
Mitra Naseri ◽  
Gholam Reza Sarvari ◽  
Niayesh Tafazoli ◽  
Nooshin Tafazoli
Keyword(s):  
Escherichia Coli ◽  
Urinary Tract ◽  
Vesicoureteral Reflux ◽  
Neurogenic Bladder ◽  
Bladder Dysfunction ◽  
Urinary System ◽  
Neurogenic Bladder Dysfunction ◽  
E Coli ◽  
Pseudomonas Species ◽  
Tract Infections

Background: Urinary tract infections (UTIs) with non-Escherichia coli (E. coli) species are associate with urological abnormalities. Objectives: To compare the prevalence of non-E. coli infections in patients with urological anomalies, neurogenic bladder dysfunction, and those with apparently normal urinary systems. Methods: Pediatric nephrology clinic at a tertiary-care center in east of Iran. Children affected by UTI enrolled from 2003 to 2016. The results of urine culture were noted at enrolment. Cases with nephrolithiasis who had normal voiding cystourethrogram were excluded. After the implementation of imaging and urodynamic examinations, 832 patients enrolled according to the following inclusion criteria: cases with vesicoureteral reflux, urinary obstruction, neurogenic bladder, and patients with apparently normal urinary tract. The prevalence of infections with E. coli vs. non-E. coli pathogens were compared between different groups of enrolled cases. Results: In this study, 62.26% of the subjects had a normal urinary system, while 33.77%, 3.97%, and 2.4% of whom had vesicoureteral reflux, neurogenic bladder, and obstruction, respectively. Non-E. coli pathogens were responsible for infections in 17.29%, 19.39%, 33.74%, and 17.15% of these cases, respectively. Infections with non-E. coli pathogens were significantly more prevalent in cases with neurogenic bladder (P = 0.003). Pseudomonas species were responsible for 4/125, 5/118, 5/28, and 0/6 episodes of non-E. coli infections in cases with apparently normal urinary system, patients with vesicoureteral reflux, cases with neurogenic bladder, and those with urinary obstruction, respectively (P = 0.004). Conclusions: Infections with non-E. coli and also Pseudomonas species are significantly more prevalent in patients with neurogenic bladder dysfunction rather than those with urological abnormalities and/or cases with apparently normal urinary system.

Sign in / Sign up

Export Citation Format

Share Document